FDA approves Lucentis to treat diabetic macular edema

The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

Home | Copyright 2008-2024 FoodandDrugRecall.org